INTRODUCTION

Adult stem cells are necessary to maintain normal tissue homeostasis in vivo and create a microenvironment (stem cell niche) required for regeneration.1,2 There are a lot of bone- or neural tissue-related diseases including osteoporosis, bone defect and malformation, neural tissue injury and defect, neurogenic heterotropic ossification, neurodegenerative diseases with ageing, fracture, injury, inflammation, etc.3-10 The stem cells could differentiate into osteoblasts or neurocytes to repair the specific tissue and treat these diseases. However, the differentiation process will be affected by different factors, especially the microenvironment. Sometimes stem cells differentiate into the required cell type not very well in microenvironment, which caused undesirable treatment of damaged tissues.11 For
example, neurogenic heterotopic ossification occurs in 25% cases of spinal cord injury, in which impaired nervous metabolic system causes chaotic bone formation surrounding neural tissue.12 This implies that directed differentiation of stem cells requires specific initiation. Therefore, understanding the differentiation regulation of osteogenesis and neurogenesis is crucial for the required tissue repair. The fate determination of stem cells requires a careful balance of genetic and epigenetic programming.13 Recent studies have identified that epigenetic regulation determines the stem cell-specific lineage differentiation.14-16 Epigenetic mechanisms can maintain the long-term regulated effects of gene expression in response to environmental stimulation.16-19 Therefore, understanding epigenetic regulation in osteogenic and neurogenic differentiation is of certain guidance for subsequent research and is crucial for promoting the differentiation efficiency and regeneration effect of bone or neural tissue.

Polycomb group complex (PcGs)-mediated chromatin leading to epigenetic repression is an important regulation mechanism, which caused the dynamic change of gene expression profiles during the differentiation and maturation of stem cells.20,21 PcGs-mediated H3K27me3 is thought to inhibit inappropriate or premature differentiation and may play a key role in determining lineage differentiation of stem cells.22,23 Human PcGs mainly consist of two subtypes, the polycomb repressive complex 1 and 2 (PRC1 and PRC2).22 PRC1 affects chromatin compactness and can block the transcriptional elongation of RNA polymerase II, thus mediating heterochromatin inhibition.23,24 PRC2, through its core component, enhancer of zeste homologue 2 (EZH2), keeps gene silencing by maintaining the silent form of histone H3 Lys27 (H3K27).25,26 These two complexes are synergistic, and PRC1 function depends on the PRC2.27 And PRC2-modified H3K27me3 is specifically recognized and bound by factors such as the PRC1 subunit CBX7 that further helps maintaining long-term gene silencing.22 This review mainly focuses on the role and mechanism of PRC2 with EZH2 as the core unit in the osteogenic and neurogenic differentiation regulation of stem cells.

2 | CORE SUBUNITS OF PRC2

The core subunits of PRC2 mainly contain four proteins: EZH1 or EZH2, suppressor of zeste 12 (SUZ12), embryo development of
the ectoderm protein (EED) and retinoblastoma binding protein (RBAP48/RBBP4 or RBAP46/RBBP7) (Figure 1A). EZH1/2, involved in PRC2 formation, contains the SET, Homology I/II and CXC domains, which form the catalytic core of histone H3K27me3 methyltransferase. The histone methyltransferase (HMTs) activity of PRC2 mainly depends on the complete SET domain in EZH protein (Figure 1B). SUZ12 contains the VEFS domain and the C–C–H–H zinc finger structure and mainly maintains PRC2 stability and assists EZH2 in exerting histone H3K27me3 methyltransferase activity (Figure 1B). EED contains the WD repeat function domain and also assists EZH2 in exerting histone H3K27me3 methyltransferase activity (Figure 1B). RBAP48 and RBAP46 contain WD repeat function domains and are involved in PRC2 formation and the subsequent binding to histone (Figure 1B).

3 | PRC2 VARIANTS

PRC2 plays an important role during epigenetic modification mediated lineage differentiation of stem cells. EZH protein is the core catalytic subunit of PRC2, EZH1 and EZH2 are 65% homologous, and EZH1 is mainly expressed in the adult tissues or the undivided cells, while EZH2 is mainly expressed in the embryonic or differentiated cells. Research finds that EZH1 and EZH2 form similar PRC2 complexes but exhibit contrasting repressive roles. PRC2-EZH2 complex is the classical form of PRC2, and this complex mainly contains four core subunits: EZH2, SUZ12, EED, and RBAP and is assembled based on the antedate formation of EZH2-EED complex (Figure 2A). As the classical form of PRC2, PRC2-EZH2 complex plays the mainly histone H3K27me3 methyltransferase activity. PRC2-EZH2 deletion affects global H3K27me2/3 levels. Compared with PRC2-EZH2, PRC2-EZH1 complex contains EZH1, SUZ12, and RBAP (Figure 2B). Its histone H3K27me3 methyltransferase activity is much lower and mainly represses transcription by directly compacting chromatin instead of methyltransferase function. PRC2-EZH1 seems to switch from a methyltransferase catalytic mechanism to a non-catalytic mechanism. Sometimes EZH1 and EZH2 may have some functional overlap in the PcG-dependent H3K27me3 regulation. The study reveals that mouse skin appears pathologic phenotypes only when EZH1 and EZH2 both delete. And EZH1 colocalizes and preferentially preserves the H3K27me3 on development-related genes to safeguard embryonic stem cells (ESCs) identity in EZH2-/- ESCs.

**FIGURE 2** The variants of PRC2 in *Homo sapiens*. (A) PRC2-EZH2 complex is the classical form of PRC2, this complex mainly contains four core subunits: EZH2, SUZ12, EED, and RBAP and is assembled based on the antedate formation of EZH2-EED complex. As the classical form of PRC2, PRC2-EZH2 complex plays the mainly histone H3K27me3 methyltransferase activity. (B) PRC2-EZH1 complex contains EZH1, SUZ12, and RBAP. Compared with PRC2-EZH2, its histone H3K27me3 methyltransferase activity is much lower and mainly represses transcription by directly compacting chromatin instead of methyltransferase function. PRC2-EZH1 seems to switch from a methyltransferase catalytic mechanism to a non-catalytic mechanism. (C) PRC2-EZH2-PCL complex is PcG-like protein (PCL) binding to PRC2-EZH2 complex. This complex containing EZH2, SUZ12, EED, RBAP, and PCL. PCL includes PCL1, PCL2, and PCL3, which is not a core subunit and this combination leads complex containing two additional PHD finger structure. PCL is mainly promotes the recruitment and facilitation of classical PRC2-EZH2 binding to the targeted CpG island and further H3K27me2 to H3K27me3 enrichment.
Depletion of EZH1 in EZH2−/− ESCs abolishes residual H3K27 methylation and derepresses the target genes. Study shows that EZH2 deletion results in myelodysplasia, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs) development in mice. Only EZH1 deletion does not cause dysplasia in nervous system, which just happens when EZH2 and EZH1 both get deleted. This suggests that EZH1 plays partial compensatory role in hematopoietic system diseases caused by EZH2 deficiency. PcG-like protein (PCL) including PCL1, PCL2 and PCL3 can also bind to PRC2 to produce another PRC2 variant and change its nature (Figure 2C). PCL is not a core subunit and is mainly involved in the recruitment and facilitation of PRC2 binding to the targeted CpG island. This complex contains two additional PHD finger structure and is mainly responsible for PRC2 recruitment and further H3K27me3 enrichment.

In summary, PRC2-EZH2 complex is the core catalytic complex of H3K27 histone methyltransferase and plays the central role in the epigenetic regulation of PcG complex.

### 4 | THE MECHANISMS OF PRC2-MEDIATED EPIGENETIC MODIFICATIONS

#### 4.1 | The interaction of non-coding RNAs and PRC2

The non-coding RNAs mainly includes microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Terminal mesodermal-specific lineage differentiation of stem cells is reported to be associated with upregulated miR-17, miR-21, miR-34a and miR-146a, along with H3K27me3 repression and reduction in PRC2 subunit SUZ12. Coinciding with osteogenic markers and the changed gene expression during the osteoblastic induction, several miRNAs such as let-7 family, miR-16, miR-21, miR-30 family, miR-155 and miR-322 are altered during osteogenic differentiation of mesenchymal stem cells (MSCs) and are designated as OsteomiR. Among these miRNAs, the miR-30d transfectants clarify the context-dependent targeting of the PRC2 subunit EED. Another miRNA, miR-101, is significantly increased during osteogenic differentiation of human bone marrow stromal cells (hBMSCs) and promotes osteogenic differentiation of hBMSCs caused by miR-101. This suggests that the miRNAs are involved in PRC2-EZH2-regulated lineage differentiation of stem cells.

IncRNAs are also regarded as a participant during the lineage commitment and maturation of the stem cell. Several PcG proteins possess RNA binding activity, which is required for further PcGs binding to DNA. EZH2, the catalytic subunit of PRC2, acts as the key IncRNA nuclear target. Moreover, at least half of the identified EZH2-binding IncRNAs are accompanied with a coding gene, either antisense or at the promoter region, suggesting EZH2 involved in local cis-regulation by IncRNAs. The IncRNA CARMEN has been reported to co-act with both EZH2 and SUZ12 to regulate the differentiation of cardiac stem cells. A IncRNA transcribed from the Kcnq1 overlapped transcript 1 (Kcnq1ot1) is highly recruited with EZH2 in the mouse brain and enhances neurogenic differentiation of mMSCs. Similarly, systematic analysis reveals the presence of an interaction between HOXA-AS3 and PRC2 subunit, HOXA-AS3 interacts with PRC2 at HOXD, and knockout of HOXA-AS3 enhances H3K27me3 at HOXD site. It has been shown HOXA-AS3 serves as an epigenetic switch of PRC2-EZH2 histone methylase modification, determining the differentiation of hBMSCs, and is necessary for H3K27me3 modification on the RUNX2 promoter, and knockdown of HOXA-AS3 enhances RUNX2 expression and osteogenic ability of hBMSC. Study found that IncRNA maternally expressed 3 (MEG3) could interact with EZH2 and contribute to PRC2-EZH2 recruitment and promote the transmission and aggregation of PRC2 complex to the specific target genes Gli2, Rian and Mirtg and lead to the differentiation of pluripotent stem cells. It has been shown that the PRC2-binding IncRNA X inactivation specific transcripts (XIST) which containing a 28 bp repetitive element repA, thus providing an example of a specific IncRNA motif that binds to the PcG complex. Another study has identified a ‘Crab-claw’ structure which visually has two-paired 4-nt loops that act as the molecular basis for IncRNA interaction.

### TABLE 1 The noncoding RNA interacted with PRC2 during the osteogenic and neurogenic differentiation of stem cells

| Noncoding RNAs | Interacted PRC2 Subunits | Stem Cells | Regulated Functions | Ref. |
|----------------|--------------------------|------------|---------------------|-----|
| MiRNAs        |                          |            |                     |     |
| miR-17         | SUZ12                    | Human amniotic fluid isolated stem cells (AF-MSCs) | Enhances osteogenic differentiation | Zentelyte et al, J cell Biochem. [40] |
| miR-21         |                          |            |                     |     |
| miR-34a        |                          |            |                     |     |
| miR-146a       |                          |            |                     |     |
| miR-30d        | EED                      | Human bone marrow stromal cells (hBMSCs)       | Enhances osteoblastic differentiation | Eguchi et al, PLOS ONE. [41] |
| miR-101        | EZH2                     | hBMSCs     | Promotes osteogenic differentiation | Wang et al, Sci Rep. [42] |
| LncRNAs        |                          |            |                     |     |
| Kcnq1ot1       | EZH2                     | mMSCs      | Recruits EZH2 in mouse brain and enhances neurogenic differentiation | Wang et al, Curr Gene Ther. [45] |
| HOTAIR         | EZH2                     | Human primary stromal cells | Promotes neural crest development | Rinn et al, Cell. [47] |
| HOXA-AS3       | EZH2                     | hBMSCs     | Represses osteogenic ability | Zhu et al, Oncotarget. [48] |
with EZH2.51,52 LncRNAs Hnf1aos1 and Gm12840 also contain the same structure that is deemed to accelerate the interaction with EZH2.45 In conclusion, the interaction of PRC2-EZH2 and ncRNAs helps in understanding its epigenetic regulation mechanism, and further studies should investigate whether ncRNAs prevent PRC2-EZH2 target binding or lead to locus-specific recruitment (Table 1).

In addition, PRC2 is required to maintain expression of maternal miRNAs and lncRNAs from the Gtl2-Rian-Mirg locus within the Dlk1-Dio3 imprinted gene cluster in mouse ESCs. In the absence of PRC2-EZH2, the entire Gtl2-Rian-Mirg locus becomes transcriptionally silent due to gain of de novo DNA methylation at the intergenic differentially methylated regions (IG-DMRs), a critical cis-regulatory element that controls expression of maternal Gtl2-Rian-Mirg locus, and further mechanistic study shows that PRC2 prevents recruitment of Dnmt3 methyltransferases.49 These indicate that the action of non-coding RNAs and PRC2 is reciprocal.

4.2 | The interaction of DNA, RNA, histone modification genes and PRC2

The interaction of PRC2-EZH2 subunit with DNA and other histone modifying enzymes has also been reported. PRC2 function and DNA methylation are typically correlated with gene repression. Analysis reveals that PRC2 physically interacts with methyltransferases DNMT3 and reduces recruitment and subsequent DNA methylation at the IG-DMR, thereby allowing for proper expression of the maternal Gtl2-Rian-Mirg locus.49 DNA dioxygenases ten-eleven translocation (TET) is responsible for DNA hydroxymethylation in osteogenic differentiation of hBMSCs. TET1 acts as a repressor of osteogenesis and recruits the co-repressor proteins EZH2 to osteogenic genes.53 The de novo DNA methyltransferase DNMT3B mediates methylation patterns may play an important role in early neurogenesis. Knockdown of DNMT3B shows a loss of H3K27me3 and EZH2 at the promoters of early neural and neural crest specifier genes during the neurogenic differentiation of hESC.54 Moreover, PRC2 function is also correlated with histone modification. Previous study finds that PRC2-EZH2 increases the H3K27me3 modification level in WNT1, WNT6, WNT10a and WNT10b promoters, thus inhibiting the further binding of histone acetyltransferases such as CBP and p300. And CBP- and p300-modified acetylation and PRC2-EZH2-modified H3K27me3 act antagonistically in regulating WNT expression.55 The H3K27me3 centred switch between EZH2 and histone lysine demethylation enzyme 6A (KDM6A) determines the hBMSCs differentiation into different lineages. The EZH2-modified H3K27me3 inhibitory marker is removed by KDM6A during the osteogenic differentiation, which then regulates the conversion of adipogenic to osteogenic differentiation through BMP/TGF and WNT signalling, and the loss of this epigenetic modification leads to development defects of bone tissue.56 In addition, SET and MYND domain containing 2 (SMYD2) directly methylates EZH2 at lysine 307 (K307) and enhances EZH2 protein stability by inhibiting its ubiquitination degradation process, which can be relieved by the histone H3K4 demethylase lysine-specific demethylase 1 (LSD1, also known as KDM1A). SMYD2 and EZH2 collaboratively participate in transcriptional repression of AXIN2, RASSF1, SIAH1, etc. The dynamic crosstalk between SMYD2 and LSD1-mediated EZH2 methylation may provide a point for the subsequent involvement of PRC2-EZH2 in the functional regulation of stem cells.56 Researchers observe the interaction between LSD1 and EZH2 proteins in MCF-7 cells. The interaction between LSD1 and EZH2 stabilizes the binding of LSD1 to IRF9 promoter, which is a key transcription factor of the interferon pathway.57 Then, the balance between H3K4me3 activation and H3K27me3 inhibition may be considered as a rheostat of targeted genes repression.58 During human cytomegalovirus (HCMV) infection process, study shows that EZH2 and its regulators Jumonji domain-containing proteins JARID2 and KDM2B repress growth factor independence 1 (GFI1). GFI1 acts as a transcriptional repressor of the HCMV immediate-early promoter (MIEP). EZH2 knockdown delays H3K27me3 in this region which accompanied by the decrease in H3K4me3.58 PRC2 functions are also related to RNA modification. Study focuses on METTL3-mediated m6A modification which plays an important role in regulating neurogenesis and neuronal development through modulating EZH2. MeRIP-seq analysis reveals that METTL3 mediates N6-methyladenosine (m6A) levels of EZH2 transcript and METTL3 inhibition downregulates EZH2 and H3K27me3 levels. The defects in neural stem cells (NSCs) proliferation, NSCs neuronal development and the facilitation of METTL3 depletion-induced NSCs glial lineage differentiation can be rescued by EZH2 overexpression.59 In summary, DNA and other histone modifying enzymes play a pivotal role in the regulation of PRC2-EZH2. Together with different modifying enzymes cross-talking, the balance between different epigenetic markers modified in the PRC2-EZH2 targets finally determine the lineage differentiation of stem cells.

4.3 | The interaction of PRC2-modified H3K27me3 and PRC1

Chromatin-modifying activities inherent to PRC1 and PRC2 play an essential role in gene regulation, cellular differentiation and development. In addition to being directly recruited to specific target sites for H3K27me3 modification, PRC2-EZH2 also functions through other mechanisms. However, no evidence has been found to prove that H3K27 methylation causes gene silencing by changing the interaction between nucleosomes.28 The current study notices that H3K27me3 modification in the PRC1 target genes provides recognition of binding sites and promotes the loci inner ring. The cyclization can promote further deposition of H3K27me3 modified PcG loci near, to prevent RNA polymerase activity. Destruction of PRC2-EZH2 reduces the binding strength of PRC1 to its chromatin target.28 Other reports show that PRC1-dependent H2AK119ub1 leads to prior recruitment of PRC2 and modification of H3K27me3, further leading to the recruitment of PRC1 to target sites. This activity is restricted to variant PRC1 complexes containing KDM2B and is important for the formation of normal polycomb domain in mouse embryonic stem cells and during
mouse development. This suggests a linkage between the PRC subunit proteins and may complete the mechanism of PRC complex-modified H3K27me3, helping to unravel the PRC2-EZH2 regulation process, and provides intervention points for more subtle links.

5 | THE ROLE OF PRC2 IN THE OSTEOPORIC DIFFERENTIATION OF STEM CELLS

It is known that craniofacial skeleton formation is crucially dependent on epigenetic regulation in senior vertebrates. Previous study shows conditional EZH2 repression causes a strong derepression in HOX expression in neural crest cells. EZH2 deletion in mesoderm and neural crest tissue causes the mortality of embryos, while EZH2 deletion in mesenchyme causes several skeletal abnormalities such as craniosynostosis and bone volume repression. During osteogenic induction in human adipose-derived stem cells (hADSCs), EZH2 expression is significantly downregulated. EZH2 inhibition enhances the osteogenic differentiation of hADSCs. Other studies have reported that conditional knockout of EZH2 inhibits osteogenesis by inducing cell cycle changes in mBMSCs, suggesting that EZH2 plays a bifunctional role during bone formation by suppressing osteogenic lineage commitment, while simultaneously facilitating the proliferative expansion of osteoprogenitor cells.

It has been identified that EZH2-modified H3K27me3 regulates the lineage specification of stem cells. EZH2 and H3K27me3 are decreased in infected pulp tissue and cells, which were similar to human dental pulp cells (hDPSCs) differentiation. The expression of EZH2 and H3K27me3 is also decreased during osteogenesis of human dental follicle stem cells (hDFSCs). EZH2 modifies H3K27me3 of RUNX2 during osteogenic differentiation of hBMSCs. Bioinformatic analysis reveals the presence of EZH2 and H3K27me3 in the promoter of osteogenic lineage-specific transcription factors FHL1, MX1 and ZBTB16. EZH2 represses FHL1, MX1 and ZBTB16 via H3K27me3 regulation, further downregulates RUNX2 expression and its downstream targets, osteopontin (OPN) and osteocalcin (OCN) and inhibits the osteogenic differentiation of hBMSCs.

Interestingly, a previous study reports that PRC2-EZH2-modified H3K27me3 is significantly increased in mBMSCs of osteoporosis mice model. H3K27me3 inhibitor DZNep effectively reduces PRC2-EZH2-modified H3K27me3 levels in the promoters of WNT1, WNT6 and WNT10a, thereby activating the WNT/β-catenin signal, and increases bone formation in osteoporosis mice. Taken together, PRC2-EZH2 regulates the osteogenic ability of stem cells mainly by modifying H3K27me3 at the promoter of osteogenic lineage-specific genes or transcription factors. H3K27me3 inhibitors (such as DZNep) or direct deletion of EZH2 (such as genetic modification by virus) can ultimately affect the osteogenic differentiation of stem cells.

**FIGURE 3** The role of PRC2 core subunits EZH2 in the osteogenic differentiation of stem cell. The core subunit of PRC2, EZH2 activates WNT1, WNT6, and Wnt10a in mBMSCs and increases bone formation of osteoporosis mice. Contrarily, inhibition of EZH2 upregulates the osteoblast-related genes FHL1, IBSP, MX1, RUNX2, SP7, and ZBTB16 in hBMSCs. With the inhibition of EZH2, the osteogenic differentiation of hADSCs and hAF-MSCs are enhanced. Knockdown of EZH2 expression shows the increased H3K27me3 level on the WNT1, WNT5A and β-catenin promoters, the activation of WNT/β-catenin signalling pathway and the upregulated osteogenesis of hDFSCs. Similarly, EZH2 deletion also upregulates β-catenin and enhances osteogenesis of hDPSCs. In pre-diabetic NOD mice model, EZH2 is found to bind to the IRF8 promoter in hBMDCs and further represses bone loss. And it has been identified that EZH2-modified H3K27me3 during the lineage specification of stem cells can be effectively reduced by CDK1, GSK126 and DZNep.
Studies have also shown that PRC2-EZH2 mediates stem cells osteogenesis in vivo. Pre-treatment with BMP2 and EZH2 inhibitor GSK126 upregulates the osteoblast-related genes COL1A1, DLX5, IBSP, OCN, RUNX2 and SP7 expression in hBMSCs on 3D scaffolds in vitro and enhances vascularization but not bone formation in vivo, suggesting that EZH2 might react to multi-facets of the osteogenesis genes which potentially support the maturation of the osteoblastic lineage.69,70 EZH2 and STAT5b-CA (constitutively active Stat5b) bind to IRF8 promoter in bone marrow-derived dendritic cells (hBMDCs) and further repress inflammation and bone loss in prediabetic NOD mice.71 But EZH2 inhibition increases bone density in adult mice and alleviates bone loss in ovariectomy osteoporosis mice model.36 In addition, GSK126 attenuates bone loss in the ovariectomy osteoporosis mouse model by inhibiting EZH2.72 Other study discovers that conditional knockout of EZH2 increases adiposity in bone marrow and causes low trabecular bone phenotype in mice.65 EZH2 deficiency potentially activates an adipogenic programme in osteogenic lineage cells. Indeed, fate-mapping studies have shown that

### TABLE 2 The role of PRC2 on the osteogenic differentiation of stem cells

| PRC2 subunits | Targeted genes | Stem cells | Regulated function | Ref. |
|---------------|----------------|------------|-------------------|------|
| EZH2          | FHL1, MX1, ZBTB16 | Human bone marrow-derived mesenchymal stem cells (hBMSCs) | Represses the osteogenic differentiation | Hemming et al, Stem Cells Dev. 2016. [13] |
| EZH2          | RUNX2          | hBMSCs and mBMSCs | Represses the osteogenic differentiation | Zhu et al, Oncotarget. 2016. [48] |
| EZH2          | HOX            | Neural crest cells | Represses the osteogenic differentiation | Schwarz et al, Development. 2014. [61] |
| EZH2          | -              | Neural crest mesenchyme cells | Represses the osteogenic differentiation; causes skeletal abnormalities | Wyngaarden et al, Development. 2011. [62] |
| EZH2          | -              | Human adipose-derived stem cells (hADSCs) | Inhibits osteogenic; enhances adipogenic differentiation | Dudakovíc et al, J Biol Chem. 2015. [64] |
| EZH2          | -              | mBMSCs | Inhibits the osteogenic differentiation; impedes cell cycle progression | Dudakovíc et al, J Biol Chem. 2018. [65] |
| EZH2          | -              | Human dental pulp cells (hDPSCs) | Represses the osteogenesis; enhances adipogenesis | Hui et al, J Endod. 2014. [66] |
| EZH2          | WNT1, WNT5A, β-Catenin | Human dental follicle stem cells (hDFSCs) | Represses the osteogenic differentiation | Deng et al, Biochem Biophys Res Commun. 2018. [67] |
| EZH2          | WNT1, WNT6, WNT10a | mBMSCs | Inhibits bone formation and enhances the excessive fat formation | Jing et al, Mol Ther. 2016. [68] |
| EZH2          | IBSP, SP7      | hBMSCs | Inhibits osteogenic and vascularization | Lui et al, Tissue Eng Part A. 2020. [69]; Dudakovíc et al, J Biol Chem. 2020. [70] |
| EZH2          | IRF8           | Human bone marrow-derived dendritic cells (hBMDCs) | Represses bone loss in prediabetic NOD mice | Zerif et al, Int J Mol Sci. 2020. [71] |
| EZH2          | -              | mBMSCs | Causes bone loss in ovariectomy osteoporosis mice | Fang et al, J Immunol. 2016. [72] |
| EZH2          | SP7            | Human bone marrow stroma cells | Inhibits osteogenic differentiation; activates adipogenic differentiation | Liu et al, PLOS ONE. 2013. [73] |
| EZH2          | -              | hBMSCs | Inhibits osteogenic differentiation | Sen et al, J Bone Miner Res. 2020. [75] |
| EZH2          | β-Catenin      | hDPSCs | Represses the osteogenic /odontogenic differentiation; | Li et al, J Dent Res. 2018. [76] |
| EZH2          | -              | hBMSCs | Inhibits the osteogenic differentiation | Wei et al, Nature Cell Biology. 2010. [78] |
| EZH2 and SUZ12 | -              | Human amniotic fluid-derived mesenchymal stem cells (AF-MSCs) | Inhibits the osteogenic differentiation | Glemžaitė et al, Stem Cells Int. 2016. [79] |
OSX<sup>Cre−</sup> cells can contain lipid droplets. Besides, EZH2 deletion enhances hDPSCs osteogenesis while impairs adipogenesis. These results hint the role of EZH2 in determining the progression of cell differentiation lineages and ultimately determine the swing between osteogenic and lipogenic differentiation.

For regulation mechanism, researchers discover that EZH2 suppresses the expression of osteogenic genes and ligand-dependent signalling pathways such as WNT, PTH and BMP to favour the adipogenic differentiation. In other study, EZH2 deletion enhances the expression of PTHr and WNT10b and the osteogenesis in MC3T3 pre-osteoblasts, and it also increases the BMP-dependent Smad1/5 phosphorylation by decreasing H3K27me3 near transcriptional start sites. WNT signalling core protein, β-catenin, promotes stem cell commitment to osteoblastic lineage and could bind to the EZH2 promoter. β-catenin deletion reduces EZH2 and H3K27me3 levels at the osteogenic loci, while EZH2 inhibition abolishes β-catenin-promoted osteoblastic commitment. Other studies show the EZH2 expression and H3K27me3 level decrease during the mineralization of hDPSCs. EZH2 overexpression represses the odontogenic differentiation ability of hDPSCs, while EZH2 mutation in SET methyltransferase domain or knockdown of EZH2 shows that EZH2 loss this repression for hDPSCs differentiation. Mechanically, EZH2 decreases β-catenin by accumulating H3K27me3 on β-catenin promoter and thereby represses the WNT/β-catenin signalling pathway. Knockdown of IncRNA MEG3 and EZH2 shows facilitative regulation of hDFSCs osteogenesis by activating the WNT/β-catenin signalling pathway via epigenetically regulating the H3K27me3 on WNT1, WNT5A and β-catenin promoters. These results indicate that EZH2 is the key to WNT/β-catenin effects on stem cells differentiation. Moreover, loss of both EZH1 and EZH2 depresses IGF signalling in chondrocytes and further skeletal growth in mice, suggesting that EZH1 and EZH2 are both required in the PRC2 function. Recently, a report has shown that cell-cycle-dependent protein kinase 1 (CDK1) represses EZH2 expression by inhibiting phosphorylation of EZH2 threonine (Thr) 487 site, which further destroys the combination of SUZ12 and EED; this results in the decrease in PRC2-EZH2 complex and enhances the osteogenic differentiation of hBMSCs. Further analysis reports that the expression of EZH2 and SUZ12 and H3K27me3 level were reduced during the osteogenic differentiation of human amniotic fluid-derived mesenchymal stem cells (hAF-MSCs). Here, the core subunits of PRC2 apply interaction during stem cell osteogenesis. The effect of EZH2 can be enriched by interacting with different components of complex.

In conclusion, these discoveries suggest that PRC2-EZH2 facilitates the early mesenchymal lineage development, but suppresses the late osteogenic lineage differentiation commitment of stem cells to functional osteoblast or osteoprogenitor cells, and serves a bi-functional role during bone formation (Figure 3 and Table 2). The long-term inhibition of EZH2 does not appear to be beneficial in adolescent or young adult osteoporosis mice model; short-term or local applications using EZH2 inhibitor in mature or engineered skeletal tissue may accelerate the maturation of differentiated osteoblasts.

**6 | THE ROLE OF PRC2 IN THE NEUROGENIC DIFFERENTIATION OF STEM CELLS**

One study suggests that EZH2 is responsible for memory, learning, spatial patterning and cognitive functions during hippocampus development in the adult mature brain. Other study has revealed that PRC2-EZH2-modified epigenetic regulation plays a critical role during spinal cord injury and repair. Recently report shows that PRC2 complex forms decreased during neurogenic differentiation.
| PRC2 subunits | Targeted genes | Stem cells | Regulated function | Ref. |
|---------------|----------------|------------|-------------------|------|
| EZH2          |                | Human neural stem cells (hNSCs) | Induces neuronal development and glial lineage differentiation | Chen et al, Genomics Proteomics Bioinformatics. 2019. [59] |
| PRC2 complexes | CDKs          | Embryonic stem cells (ESCs)       | Enhances the neuronal differentiation | Fukasawa et al, J Biochem. 2015. [82] |
| EZH2          | GFAP           | Neuronal progenitor cells (NPCs)   | Represses the neurogenic competence and promoted the astrogenic fate | Sparmann et al, EMBO J. 2013. [87] |
| EZH2          |                | Mouse neural stem cells (mNSCs)   | Increases oligodendrocyte formation; decreased astrocyte formation | Sher et al, Stem Cells. 2008. [88] |
| EZH2          |                | NPCs                                   | Increases mdDA neuron formation during neural development | Wever et al, Front Mol Neurosci. 2018. [95] |
| EZH2          |                | Ventral midbrain-derived neural stem cells (VM-NSCs) | Enhances the differentiation into DA neurons | Hong et al, Stem Cells Dev. 2019. [96] |
| EZH2          | p21WAF1/CP     | neural progenitor                      | Maintains neuroepithelial structure | Akizu et al, Open Biol. 2016. [99] |
| EZH2          | ASCL1a NGN1    | NSCs                                   | Promotes neurons differentiation | Li et al, Stem Cell Res Ther. 2019. [100] |
| EED           |                | NSCs                                   | Promotes neurosphere formation | Sun et al, Cereb Cortex. 2018. [102] |
| EED           | SUZ12          | NSCs                                   | Causes neural tube defects in rats | Wang et al, Neurosci Lett. 2010. [104] |
| EZH2 and EED  |                | NPCs                                   | Prolongs the neurogenic phase; delays the astrogenic phase | Hirabayashi et al, Neuron. 2009. [105] |
of hESCs. Neurogenesis begins after the ectodermal cells differentiate into the neuroepithelial cells by neural induction, followed by neurulation. Neurulation is followed by neural tube formation from neural plates. Then, neural tube is patterned to generate special regions and also gives rise to neural epithelial cells (NECs), mature neurons and glial cells. After several rounds of proliferation, NECs generate neural progenitor cells (NPCs) or NSCs. NPCs/NSCs seem to differentiate into neurons firstly and later astrocytes during the neocortical development; this neurogenic-to-astrogenic fate switch determines the final repaired neuron generation. Researchers find that EZH2 maintains NPCs self-renewal and the neurogenic-to-astrogenic fate switch of NPCs. In addition, EZH2 represses the neurogenic and promotes the astrogenic fate transition of NPCs.

Another study has shown that EZH2 expression decreases during the neuronal differentiation and is completely inhibited during the differentiation into astrocytes of mNSCs. Neuroepithelial cells in ventricular and subventricular zone (VZ and SVZ) produce radial glial cells (RGCs). The differentiated RGCs produce mature neural cells, while quiescent RGCs form NSCs, which thereafter control SVZ neurogenesis including differentiation into neurons, astrocytes and oligodendrocytes. EZH2 is required for NSCs self-renewal and restricted during the astrogenesis of the cells in the SVZ of adult murine brain. High level of EZH2 increases oligodendrocyte formation and decreases astrocyte formation from NSCs. And EZH2 is abundantly expressed in immature neurons, whereas its expression significantly reduced during the maturation of hippocampal neurons.

Moreover, EZH2 regulates the generation of mesodiencephalic dopaminergic (mDA) neuron and maintains the proper subset identity and the survival of different mDA neurons during neural development. Knockdown of EZH2 effectively promotes mDA neuronal differentiation during midbrain development. Conditional knockout of EZH2 produces ectopic mDA neurons in the ischemic organizer (IsO) of mice hindbrain. These suggest that PRC2-EZH2 participates in the progress of neural differentiation of stem cells and functional neural structure formation by supporting the generation, maturation and maintenance of differential neural lineage.

Then, epigenetic mechanism shows that EZH2 mediates the ubiquitination and proteasomal degradation of aggregated phospho-serine 129 (pSer129) α-Syn, thus having a neuroprotective anti-inflammatory potential, oxidative stress reduction and apoptosis prevention. It is found that EZH2/H3K27me3 levels are elevated in the rat spinal cord after nerve injury. EZH2 directly represses cell cycle regulator p21/WAF1/CIP in the chicken spinal cord. EZH2 deletion reduces neural progenitor proliferation and shuffles the neuroepithelium (NE) structure of chick embryo neural tubes, correlating with alteration of the Rho pathway, which is essential for maintaining the neuroepithelial structure. SOX19b knockdown decreases the EZH2 upsurge and H3K27me3 at the promoters of ASCL1a and NGN1, thereby reducing NSCs proliferation and premature differentiation into neurons. The selective EZH2 inhibitor EPZ005687 effectively reduces the H3K27me3 level in ventral midbrain-derived NSCs (VM-NSCs) and enhances its differentiation into mDA neurons. A study has reported a crosstalk between RNA m6A modification and histone modifications. METTL3-mediated m6A modification plays an important role in regulating neurogenesis and neuronal development through modulating EZH2. MeRIP-seq analysis reveals that METTL3 mediates m6A levels of EZH2 transcript and METTL3 inhibition downregulates EZH2 and H3K27me3 levels. The defects in NSCs proliferation, NSCs neuronal development and the facilitation of METTL3 depletion-induced NSCs glial lineage differentiation can be rescued by EZH2 overexpression. Moreover, the core subunits of PRC2 co-work during neural differentiation. EED is also essential for spinal cord development and required for neurosphere formation and NSCs proliferation in the SVZ region. EED is highly expressed in the neural tube, and downregulation of EED causes defects in neural tube. Correspondingly, EED deletion decreases the SUZ12 and H3K27me3 levels in sacral cords of rats with neural tube defects (NTDs). Inactivation of PRC2-EZH2 by knockout of EZH2 or EED prolongs neurogenic phase and delays astrogeneic phase of NPCs. Further, PRC2-EZH2 is found to repress the expression of Neurogenin-1 in a developmental-stage-dependent manner. The above points indicate that PRC2-EZH2 acts as the temporal regulator of neurogenic fate in stem cell and inhibits the differentiation of stem cells to functional neurogenic cells, suggesting that it is the key target point for neurogenic regulation (Figure 4 and Table 3).

### 7 CONCLUSIONS

In summary, as the core catalytic component of H3K27 histone methyltransferase, the PRC2 has robust regulatory effects on osteogenic and neurogenic differentiation of stem cells via epigenetic mechanisms, and PRC2-EZH2 acts as the typical variant form of PRC2 complex. Its regulation function is usually associated with the interaction of ncRNAs, histone acetyltransferases (HATs), histone demethylase (HDMs), DNA methyltransferase (DNMs) and the cross-talking between PRC2 and PRC1. The information in this review may help to further clarify PRC2-EZH2 role and the deep modification rules in osteogenic/neurogenic differentiation of stem cells and provides potential targets to regulate the associated function of PRC2-EZH2. Since the known regulated target of PRC2-EZH2 and H3K27me3 mainly relies on epigenetic inhibition or direct deletion of EZH2, further study may focus on the core functional fragments and bio-active modulators of PcGs protein, which may improve the fine regulation of PRC2-EZH2, control the specific differentiation initiation and transformation of stem cells and enhance the regeneration of bone or neural tissues and the therapy of diseases involving bone or neural tissues.

### ACKNOWLEDGEMENTS

This work was supported by grants from the National Natural Science Foundation of China (81625005 to ZPF), CAMS Innovation Fund for Medical Sciences (2019-I2 M-5-031 to ZPF), the Programme for ‘Hundred-Thousand- Ten Thousand’ Talents in Beijing (2018A16 to ZPF) and Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction (KFKT2019012 to L.L).
CONFLICT OF INTEREST
The authors declare no potential conflicts of interest.

DATA AVAILABILITY STATEMENT
All data used to support the findings of this study are included within the article.

ORCID
Zhipeng Fan https://orcid.org/0000-0003-0629-3476

REFERENCES
1. Vizoso F, Eiro N, Costa L, et al. Mesenchymal stem cells in homeostasis and systemic diseases: Hypothesis, evidences, and therapeutic opportunities. Int J Mol Sci. 2019;20(15):3738.
2. Schellenberg A, Lin Q, Schüler H, et al. Replicative senescence of mesenchymal stem cells causes DNA-methylation changes which correlate with repressive histone marks. Aging (Albany, NY). 2011;3(9):873-888.
3. Alippe Y, Mbalaviele G. Omnipresence of inflammosome activities in inflammatory bone diseases. Semin Immunopathol. 2019;41(5):607-618.
4. Meinberg EG, Clark D, Miclau KR, Marcucio R, Miclau T. Fracture repair in the elderly: Clinical and experimental considerations. Injury. 2019;50(Suppl 1):S62-S65.
5. Montalcini T, Romeo S, Ferro Y, et al. Osteoporosis in chronic inflammatory disease: the role of malnutrition. Endocrine. 2013;43(1):59-64.
6. Liang Z, Zhao Y, Ruan L, et al. Impact of aging immune system on neurodegeneration and potential immunotherapies. Prog Neurobiol. 2017;157:2-28.
7. Xiao Y-Z, Yang MI, Xiao YE, et al. Reducing Hypothalamic Stem Cell Senescence Protects against Aging-Associated Physiological Decline. Cell Metab. 2020;31(3):534-548.
8. Hayashi M, Nakashima T, Yoshimura N, et al. Autoregulation of Osteocyte Sema3A Orchestrates Estrogen Action and Counteracts Bone Aging. Cell Metab. 2019;29(3):627-637.
9. Bollaerts I, Van Houcke J, Andries L, De Groef L, Moons L. Neuroinflammation as Fuel for Axonal Regeneration in the Injured Vertebrate Central Nervous System. Mediators Inflamm. 2017;2017:9478542.
10. Bickford PC, Flowers A, Grimmig B. Aging leads to altered microglial function that reduces brain resiliency increasing vulnerability to neurodegenerative diseases. Exp Gerontol. 2017;94:4-8.
11. Maisani M, Pezzoli D, Chassande O, Mantovani D. Cellularizing hydrogel scaffolds to repair bone tissue: How to create a physiologically relevant micro-environment? J Tissue Eng. 2017;8:2041731417712073.
12. da Paz AC, Carod Artal FJ, Kalil RK. The function of proprionceptors in bone organization: a possible explanation for neurogenic heterotopic ossification in patients with neurological damage. Med Hypotheses. 2007;68(1):67-73.
13. Hemming S, Cakouros D, Vandyke K, et al. Identification of novel EZH2 targets regulating osteogenic differentiation in mesenchymal stem cells. Stem Cells Dev. 2016;25(12):909-921.
14. Ringe J, Burmester GR, Sittinger M. Regenerative medicine in rheumatic disease-progress in tissue engineering. Nat Rev Rheumatol. 2012;8(8):493-498.
15. Cakouros D, Gronthos S. Epigenetic regulation of bone marrow stem cell aging: Revealing epigenetic signatures associated with hematopoietic and mesenchymal stem cell aging. Aging Dis. 2019;10(1):174-189.
16. de Almeida D, Ferreira M, Franzen J, et al. Epigenetic classification of human mesenchymal stromal cells. Stem Cell Rep. 2016;6(2):168-175.
17. Im GJ, Shin KJ. Epigenetic approaches to regeneration of bone and cartilage from stem cells. Expert Opin Biol Ther. 2015;15(2):181-193.
18. Roelofs AJ, Rocke JP, De Bari C. Cell-based approaches to joint surface repair: A research perspective. Osteoarthr Cartil. 2013;21(7):892-900.
19. Deimling SJ, Lau K, Hui CC, Hopyan S. Genetic interaction between GlI3 and Ezh2 during limb pattern formation. Mech Dev. 2018;151:30-36.
20. Pasini D, Bracken AP, Hansen JB, Capillo M, Helin K. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol. 2007;27(10):3769-3779.
21. Ezhkova E, Lien W-H, Stokes N, et al. EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev. 2011;25(5):485-498.
22. Wang L, Jin Q, Lee JE, Su IH, Ge K, Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc Natl Acad Sci USA. 2010;107(16):7317-7322.
23. Hemming S, Cakouros D, Isenmann S, et al. Ezh2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification. Stem Cells. 2014;32(3):802-815.
24. Kuzmichev A, Jenuwein T, Tempst P, Reinberg D. Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell. 2004;14(2):183-193.
25. Adamik J, Roodman GD, Galson DL. Epigenetic-based mechanisms of osteoblast suppression in multiple myeloma bone disease. JBMRI Plus. 2019;3(3):e10183.
26. Alzrigat M, Jernberg-Wiklund HJ, Licht JD. Targeting EZH2 in multiple myeloma-multifaceted anti-tumor activity. Epigenomes. 2018;2(3):16.
27. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298(5595):1039-1043.
28. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: Knowns and unknowns. Nat Rev Mol Cell Biol. 2009;10(10):697-708.
29. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 2002;16(22):2893-2905.
30. Penfornis P, Fernandes JD, Pochampally R. Polycomb group protein Suz12 is regulated by a novel miRNA-like small RNA. Sci Rep. 2018;8(1):1720.
31. Dubey N, Hoffman JF, Schuebel K, et al. The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder. Mol Psychiatry. 2017;22(8):1172-1184.
32. Longo JF, Brosius SN, Black L, et al. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms. Cell Commun Signal. 2019;17(1):74.
33. Schuettingeruber B, Bourbon HM, Di Croce LD, Cavalli G. Genome regulation by polycomb and trithorax: 70 years and counting. Cell. 2017;171(1):34-57.
34. Margueron R, Li G, Sarma K, et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell. 2008;32(4):503-518.
35. Vo LT, Kinney MA, Liu X, et al. Regulation of embryonic haematopoietic multipotency by Ezh2. Nature. 2018;553(7689):506-510.
36. Dudakovc A, Camilleri ET, Riester SM, et al. Enhancer of zeste homolog 2 inhibition stimulates bone formation and mitigates bone loss caused by ovarietomy in skeletally mature mice. J Biol Chem. 2016;291(47):24594-24606.
37. Shen X, Liu Y, Hsu Y-J, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell. 2008;32(4):491-502.

38. Mochizuki-Kashio M, Aoyama K, Sashida G, et al. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner. Blood. 2015;126(10):1172-1183.

39. Brien GL, Healy E, Jerman E, et al. A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence. Genes Dev. 2015;29(21):2231-2243.

40. Zentelytė A, Gasiūnienė M, Treigytė G, et al. Epigenetic regulation of amniotic fluid mesenchymal stem cell differentiation to the mesodermal lineages at normal and fetus-diseased gestation. J Cell Biochem. 2020;121(2):1811-1822.

41. Eguchi T, Watanabe K, Hara ES, et al. OstemiR: A novel panel of microRNA biomarkers in osteoblastic and osteocytic differentiation from mesenchymal stem cells. PLoS One. 2013;8(3):e58796.

42. Wang H, Meng Y, Cui Q, et al. MiR-101 Targets the EZH2/Wnt/β-Catenin the Pathway to Promote the Osteogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells. Sci Rep. 2016;6:36988.

43. Li N, Long B, Han W, Yuan SM, Wang K. MicroRNAs: Important regulators of stem cells. Stem Cell Res Ther. 2017;8(1):110.

44. Ounzain S, Micheletti R, Arnan C, et al. CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. J Mol Cell Cardiol. 2015;89:98-112.

45. Wang Y, Xie Y, Li L, et al. EZH2 RIP-seq identifies tissue-specific long non-coding RNAs. Curr Gene Ther. 2018;18(5):275-285.

46. Terranova R, Yokobayashi S, Stadler MB, et al. Polycomb group proteins Ezh2 and Rnf2 direct genomic contraction and imprined repression in early mouse embryos. Dev Cell. 2008;15(5):668-679.

47. Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007;129(7):1311-1323.

48. Zhu X-Y, Yan Y-W, Chen D, et al. Long non-coding RNA Hoxa-AS3 interacts with EZH2 to regulate lineage commitment of mesenchymal stem cells. Oncotarget. 2016;7(39):63561-63570.

49. Das P, Hendrix D, Apostolou E, et al. PRC2 Is Required to Maintain Expression of the Maternal Gtl2-ri-Ran-Mirg Locus by Preventing De Novo DNA Methylation in Mouse Embryonic Stem Cells. Cell Rep. 2015;12(9):1456-1470.

50. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycetyl proteins targeted by a short repeat RNA to the mouse X chromosome. Science. 2008;322(5902):750-756.

51. Wu L, Murat P, Matak-Vinkovic D, Murrell A, Balasubramanian S. Binding interactions between long noncoding RNA HOTAIR and PRC2 proteins. Biochemistry. 2013;52(52):9519-9527.

52. Wang Z, Zhang X-J, Ji Y-X, et al. The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat Med. 2016;22(10):1131-1139.

53. Cakouros D, Hemming S, Gronthos K, et al. Specific functions of TET1 and TET2 in regulating mesenchymal cell lineage determination. Epigenetics Chromatin. 2019;12(1):3.

54. Martins-Taylor K, Schroeder DI, LaSalle JM, Lalande M, Xu RH. Role of DNMT3B in the regulation of early neural and neural crest specifiers. Epigenetics. 2012;7(1):71-82.

55. He A, Ma Q, Cao J, et al. Polycetyl repressive complex 2 regulates normal development of the mouse heart. Circ Res. 2012;110(3):406-415.

56. Zeng YI, Qiu R, Yang Y, et al. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis. Cell Rep. 2019;29(6):1482-1498.

57. Jin Y, Hua BO, Fu X, et al. LSD1 collaborates with EZH2 to regulate expression of interferon-stimulated genes. Biomed Pharmacother. 2017;88:728-737.

58. Sourvinos G, Morou A, Sanidas I, et al. The downregulation of GF1 by the EZH2-NDY1/KDM2B-JARID2 axis and human cytomegalovirus (HCMV) associated factors allows the activation of the HCMV major IE promoter and the transition to productive infection. PLoS Pathog. 2014;10(5):e1004136.

59. Chen J, Zhang Y-C, Huang C, et al. m6A regulates neurogenesis and neuronal development by modulating histone methyltransferase EzH2. Genomics Proteomics Bioinformatics. 2019;17(2):154-168.

60. Blackledge N, Farcas A, Kondo T, et al. Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2 recruitment and polycomb domain formation. Cell. 2014;157(6):1445-1459.

61. Schwarz D, Varum S, Zemke M, et al. EzH2 is required for neural crest-derived cartilage and bone formation. Development. 2014;141(4):867-877.

62. Wyngaarden LA, Delgado-Olguin P, Su IH, Bruneau BG, Hopyan S. Ezh2 regulates anteroposterior axis specification and proximodistal axis elongation in the developing limb. Development. 2011;138(17):3759-3767.

63. Dudakov A, Gluscevic M, Paradise CR, et al. Profiling of human epigenetic regulators using a semi-automated real-time qPCR platform validated by next generation sequencing. Gene. 2017;609:28-37.

64. Dudakov A, Camilleri ET, Xu F, et al. Epigenetic control of skeletal development by the histone methyltransferase Ezh2. J Biol Chem. 2015;290(46):27604-27617.

65. Dudakov A, Camilleri ET, Paradise CR, et al. Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice. J Biol Chem. 2018;293(33):12894-12907.

66. Hui T, A P, Zhao Y, et al. EZH2, a potential regulator of dental pulp inflammation and regeneration. J Endod. 2014;40(8):1132-1138.

67. Deng L, Hong H, Zhang X, et al. Down-regulated IncRNA MEG3 promotes osteogenic differentiation of human dental follicle stem cells by epigenetically regulating Wnt pathway. Biochem Biophys Res Commun. 2018;503(3):2061-2067.

68. Jing H, Liao Li, An Y, et al. Suppression of EZH2 prevents the shift of osteoprotic MSC fate to adipocyte and enhances bone formation during osteoporosis. Mol Ther. 2016;24(2):217-229.

69. Lui H, Samsonraj RM, Vaquette C, et al. Combination of BMP2 and EZH2 inhibition to stimulate osteogenesis in a 3D bone reconstruction model. Tissue Eng A. 2021. https://doi.org/10.1089/ten.TEA.2020.0218

70. Dudakov A, Samsonraj RM, Paradise CR, et al. Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2. J Biol Chem. 2020;295(23):7877-7893.

71. Zerif E, Khan FU, Raki AA, et al. Elucidating the role of Ezh2 in tolerogenic function of NOD bone marrow-derived dendritic cells expressing constitutively active Stat5b. Int J Mol Sci. 2020;21(18):6453.

72. Fang C, Qiao YU, Mun SH, et al. Cutting edge: EZH2 promotes osteoclastogenesis by epigenetic silencing of the negative regulator IRF8. J Immunol. 2016;196(11):4452-4456.

73. Liu Y, Strecker S, Wang L, et al. Osterix-cre labeled progenitor cells contribute to the formation and maintenance of the bone marrow stroma. PLoS One. 2013;8(8):e71318.

74. Chen J, Shi YU, Regan J, et al. Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice. PLoS One. 2014;9(1):e85161.

75. Sen B, Paradise CR, Xie Z, et al. β-catenin preserves the stem state of murine bone marrow stromal cells through activation of EZH2. J Bone Miner Res. 2020;35(6):1149-1162.
76. Li B, Yu F, Wu F, et al. EZH2 Impairs Human Dental Pulp Cell Mineralization via the Wnt/β-Catenin Pathway. J Dent Res. 2018;97(5):571-579.

77. Lui JC, Garrison P, Nguyen Q, et al. EZH1 and EZH2 promote skeletal growth by repressing inhibitors of chondrocyte proliferation and hypertrophy. Nat Commun. 2016;7:13685.

78. Wei Y, Chen Y-H, Li L-Y, et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27m and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol. 2011;13(1):87-94.

79. Glemžaitė M, Navakauskienė R. Osteogenic differentiation of human amniotic fluid mesenchymal stem cells is determined by epigenetic changes. Stem Cells Int. 2016;2016:6465307.

80. Zhang J, Ji F, Liu Y, et al. Ezh2 regulates adult hippocampal neurogenesis and memory. J Neurosci. 2014;34(15):5184-5199.

81. Dang L, Tropepe V. Neural induction and neural stem cell development. Regen Med. 2006;1(5):635-652.

82. Miller FD, Gauthier AS. Timing is everything: Making neurons versus glia in the developing cortex. Neuron. 2007;54(3):357-369.

83. Götz M, Huttmann WB. The cell biology of neurogenesis. Nat Rev Mol Cell Biol. 2005;6(10):777-788.

84. Sun B, Chang E, Gerhartl A, Szele FG. Polycomb protein EED is required for neurogenesis from embryonic to adult stage. Front Mol Neurosci. 2010;15:1018-1022.

85. Götz M, Huttner WB. The cell biology of neurogenesis. Nat Rev Mol Cell Biol. 2005;6(10):777-788.

86. Sparmann A, Verhoefen E, et al. The chromodomain helicase Chd4 is required for Polycomb-mediated inhibition of astroglial differentiation. EMBO J. 2013;32(11):1598-1612.

87. Sher F, Rößler R, Brouwer N, et al. Polycomb group protein Ezh2. Stem Cells. 2008;26(11):2875-2883.

88. Kriegstein AR, Götz M. Radial glia diversity: A matter of cell fate. Glia. 2003;43(1):37-43.

89. Zhang J, Ji F, Liu Y, et al. Ezh2 regulates adult hippocampal neurogenesis and memory. J Neurosci. 2014;34(15):5184-5199.

90. Sun B, Chang E, Gerhartl A, Szele FG. Polycomb protein EED is required for neurogenesis from embryonic to adult stage. Front Mol Neurosci. 2010;15:1018-1022.

91. Sardoiwala MN, Srivastava AK, Kaundal B, Karmakar S, Choudhury SR. Recuperative effect of metformin loaded polydopamine nanoformulation promoting EZH2 mediated proteasomal degradation of phospho-α-synuclein in Parkinson’s disease model. Nanomedicine. 2020;24:102088.

92. Akizuki N. Martínez-Balbás MA. EZH2 orchestrates apicobasal polarity and neuroepithelial cell renewal. Neurogenesis (Austin). 2016;3(1):e1250034.

93. Akizuki N, García MA, Estarás C, et al. EZH2 regulates neuroepithelial structure and neuroblast proliferation by repressing p21. Open Biol. 2016;6(4):150227.

94. Wang C, Zhao JJ, Lu CL, et al. Polycomb group proteins are essential for spinal cord development. Front Biosci (Landmark Ed). 2010:15:1018-1022.

95. Song P-P, Hu Y, Liu C-M, et al. Embryonic ectoderm development protein is regulated by microRNAs in human neural tube defects. Am J Obstet Gynecol. 2011;204(6):544.

96. Wang Y, Guan Y, Wang F, et al. Bmi-1 regulates self-renewal, proliferation and senescence of human fetal neural stem cells in vitro. Neurosci Lett. 2010;476(2):74-78.

97. Hirabayashi Y, Suzuki N, Tsuibo M, et al. Polycomb limits the neurogenic competence of neural precursor cells to promote astrogenic fate transition. Neuron. 2009;63(5):600-613.